(Reuters) - AstraZeneca topped analysts' estimates for quarterly profit and reiterated its targets for the year on Wednesday, as the British drugmaker benefited from higher demand for some of its ...

(Reuters) - British drugmaker AstraZeneca forecast revenue growth for this year of around 10% on Friday, as it factored in a hit from the coronavirus outbreak in China and fell short of analysts' ...

AstraZeneca Plc has agreed to develop an antibody-based therapy with Swiss biotechnology firm Neurimmune for a rare, ...

AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. | AstraZeneca has scrapped an asthma program after the FLAP inhibitor flunked a phase 2 trial.

AstraZeneca Plc shares plunged in London, erasing about £14 billion ($18 billion) of market value, amid escalating concerns over a Chinese probe into the UK drugmaker. Traders cited a report from the ...